Literature DB >> 21601600

Targeted therapy of liver fibrosis/cirrhosis and its complications.

Klaas Poelstra1, Detlef Schuppan2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21601600     DOI： 10.1016/j.jhep.2011.04.008

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  15 in total

Review 1.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors:  Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Curr Cancer Drug Targets       Date:  2012-11-01       Impact factor: 3.428

2.  Retinol binding protein-albumin domain III fusion protein deactivates hepatic stellate cells.

Authors:  Sangeun Park; Soyoung Choi; Min-Goo Lee; Chaeseung Lim; Junseo Oh
Journal:  Mol Cells       Date:  2012-11-15       Impact factor: 5.034

3.  Hepatic stellate cell-targeted delivery of hepatocyte growth factor transgene via bile duct infusion enhances its expression at fibrotic foci to regress dimethylnitrosamine-induced liver fibrosis.

Authors:  Balakrishnan Chakrapani Narmada; Yuzhan Kang; Lakshmi Venkatraman; Qiwen Peng; Rashidah Binte Sakban; Bramasta Nugraha; Xuan Jiang; Ralph M Bunte; Peter T C So; Lisa Tucker-Kellogg; Hai-Quan Mao; Hanry Yu
Journal:  Hum Gene Ther       Date:  2013-05       Impact factor: 5.695

Review 4.  Evolving therapies for liver fibrosis.

Authors:  Detlef Schuppan; Yong Ook Kim
Journal:  J Clin Invest       Date:  2013-05-01       Impact factor: 14.808

Review 5.  Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies.

Authors:  Don C Rockey
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-07       Impact factor: 11.382

Review 6.  Drug delivery nanosystems targeted to hepatic ischemia and reperfusion injury.

Authors:  Margarida Ferreira-Silva; Catarina Faria-Silva; Pedro Viana Baptista; Eduarda Fernandes; Alexandra Ramos Fernandes; Maria Luísa Corvo
Journal:  Drug Deliv Transl Res       Date:  2021-03-03       Impact factor: 4.617

7.  Class II HDAC inhibition hampers hepatic stellate cell activation by induction of microRNA-29.

Authors:  Inge Mannaerts; Nathalie Eysackers; Oscar O Onyema; Katrien Van Beneden; Sergio Valente; Antonello Mai; Margarete Odenthal; Leo A van Grunsven
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

8.  Targeted recombinant fusion proteins of IFNγ and mimetic IFNγ with PDGFβR bicyclic peptide inhibits liver fibrogenesis in vivo.

Authors:  Ruchi Bansal; Jai Prakash; Marieke De Ruiter; Klaas Poelstra
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

9.  Experimental liver fibrosis research: update on animal models, legal issues and translational aspects.

Authors:  Christian Liedtke; Tom Luedde; Tilman Sauerbruch; David Scholten; Konrad Streetz; Frank Tacke; René Tolba; Christian Trautwein; Jonel Trebicka; Ralf Weiskirchen
Journal:  Fibrogenesis Tissue Repair       Date:  2013-10-01

10.  A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis.

Authors:  Jérémie Gautheron; Mihael Vucur; Florian Reisinger; David Vargas Cardenas; Christoph Roderburg; Christiane Koppe; Karina Kreggenwinkel; Anne Theres Schneider; Matthias Bartneck; Ulf Peter Neumann; Ali Canbay; Helen Louise Reeves; Mark Luedde; Frank Tacke; Christian Trautwein; Mathias Heikenwalder; Tom Luedde
Journal:  EMBO Mol Med       Date:  2014-08       Impact factor: 12.137
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.